bluebird bio Inc (BLUE) : Casdin Capital scooped up 2,500 additional shares in bluebird bio Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 122,500 shares of bluebird bio Inc which is valued at $6,958,000.bluebird bio Inc makes up approximately 6.10% of Casdin Capital’s portfolio.
Other Hedge Funds, Including , Price T Rowe Associates Inc Md boosted its stake in BLUE in the latest quarter, The investment management firm added 283,718 additional shares and now holds a total of 2,444,381 shares of bluebird bio Inc which is valued at $138,840,841. bluebird bio Inc makes up approx 0.03% of Price T Rowe Associates Inc Md’s portfolio. Ghost Tree Capital added BLUE to its portfolio by purchasing 170,000 company shares during the most recent quarter which is valued at $9,656,000. bluebird bio Inc makes up approx 3.97% of Ghost Tree Capital’s portfolio.Renaissance Technologies boosted its stake in BLUE in the latest quarter, The investment management firm added 43,900 additional shares and now holds a total of 82,500 shares of bluebird bio Inc which is valued at $4,686,000. bluebird bio Inc makes up approx 0.01% of Renaissance Technologies’s portfolio.Fmr boosted its stake in BLUE in the latest quarter, The investment management firm added 2,312 additional shares and now holds a total of 5,541,457 shares of bluebird bio Inc which is valued at $314,754,758. bluebird bio Inc makes up approx 0.04% of Fmr’s portfolio.
bluebird bio Inc closed down -0.01 points or -0.02% at $49.33 with 5,95,771 shares getting traded on Thursday. Post opening the session at $49.5, the shares hit an intraday low of $48.67 and an intraday high of $50.1899 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, bluebird bio Inc reported $-1.59 EPS for the quarter, missing the analyst consensus estimate by $ -0.09 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-1.50. The company had revenue of $1.55 million for the quarter, compared to analysts expectations of $2.01 million. The company’s revenue was down -68.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-1.57 EPS.
Many Wall Street Analysts have commented on bluebird bio Inc. Shares were Reiterated by Maxim Group on Aug 4, 2016 to “Buy” and Lowered the Price Target to $ 85 from a previous price target of $105 .bluebird bio Inc was Initiated by Cantor Fitzgerald to “Hold” on Jun 3, 2016.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.